WallStreetZenWallStreetZen

NASDAQ: NLTX
Neoleukin Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

NLTX past revenue growth

How has NLTX's revenue growth performed historically?
Company
N/A
Industry
266.89%
Market
21.77%
NLTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NLTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

NLTX earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$57.6M
Current Profit Margin
0%

NLTX Return on Equity

Current Company
-51.5%
Current Industry
16.8%
Current Market
188.7%
NLTX's Return on Equity (-47.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when NLTX announces earnings.

NLTX Return on Assets

Current Company
-43.5%
Current Industry
4.7%
NLTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

NLTX Return on Capital Employed

Current Company
-54.88%
Current Industry
10.8%
NLTX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NLTX vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
NLTX$0.00-$56.68M-$59.28M-100.00%N/A
CPIX$42.01M$412.72k-$5.57M+0.41%N/A
FLGCN/AN/AN/AN/AN/A
DERM$75.22M-$23.71M-$40.74M+26.76%N/A
MDVL$39.04M-$44.24M-$49.17M+150.47%N/A
View Top Pharmaceutical Stocks

NLTX earnings dates

Next earnings date
May 8, 2023

Neoleukin Therapeutics Earnings & Revenue FAQ

What were NLTX's earnings last quarter?

On Invalid Date, Neoleukin Therapeutics (NASDAQ: NLTX) reported Q4 2022 earnings per share (EPS) of -$0.24, up 11.11% year over year. Total Neoleukin Therapeutics earnings for the quarter were -$13.45 million. In the same quarter last year, Neoleukin Therapeutics's earnings per share (EPS) was -$0.27.

If you're new to stock investing, here's how to buy Neoleukin Therapeutics stock.

What was NLTX's earnings growth in the past year?

As of Q1 2023, Neoleukin Therapeutics's earnings has grown year over year. Neoleukin Therapeutics's earnings in the past year totalled -$59.28 million.

What is NLTX's earnings date?

Neoleukin Therapeutics's earnings date is Invalid Date. Add NLTX to your watchlist to be reminded of NLTX's next earnings announcement.

What was NLTX's revenue last quarter?

On Invalid Date, Neoleukin Therapeutics (NASDAQ: NLTX) reported Q4 2022 revenue of $0.00 up N/A year over year. In the same quarter last year, Neoleukin Therapeutics's revenue was $0.00.

What was NLTX's revenue growth in the past year?

As of Q1 2023, Neoleukin Therapeutics's revenue has grown null year over year. Neoleukin Therapeutics's revenue in the past year totalled $0.00.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.